Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PLA2G7 | Q13093 | 2/20 | 0.35 |
| ▸ | PDE3B | Q13370 | 4/20 | 0.33 |
| ▸ | PDE3A | Q14432 | 4/20 | 0.33 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.33 |
| ▸ | HRH1 | P35367 | 1/20 | 0.33 |
| ▸ | ADRA1B | P35368 | 1/20 | 0.33 |
| ▸ | MPO | P05164 | 1/20 | 0.32 |
| ▸ | CLPP | Q16740 | 2/20 | 0.31 |
| ▸ | TOP2A | P11388 | 1/20 | 0.31 |
| ▸ | TOP2B | Q02880 | 1/20 | 0.31 |
| ▸ | P2RX7 | Q99572 | 2/20 | 0.30 |
| ▸ | MMP13 | P45452 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6289382 | 0.84 | MMP13 (0.38) | PLA2G7PDE3BPDE3AMMP13 | |
| SCHEMBL6289335 | 0.80 | PDE3B (0.38) | PLA2G7PDE3BPDE3AADRA1AHRH1 | |
| SCHEMBL6289368 | 0.78 | KDM5A (0.38) | PLA2G7ADRA1AHRH1ADRA1BMPO | |
| SCHEMBL6289023 | 0.77 | CNR2 (0.41) | MMP13 | |
| SCHEMBL6701186 | 0.76 | MMP13 (0.41) | PDE3BPDE3AMMP13 | |
| SCHEMBL6289024 | 0.73 | PLA2G7 (0.33) | PLA2G7PDE3BPDE3AADRA1AHRH1 | |
| SCHEMBL6292736 | 0.73 | PLA2G7 (0.33) | PLA2G7 | |
| SCHEMBL6814878 | 0.71 | ALDH1A1 (0.41) | MMP13 | |
| SCHEMBL6489375 | 0.70 | GRM4 (0.33) | PLA2G7ADRA1AHRH1ADRA1BMPO | |
| SCHEMBL6698566 | 0.70 | MMP13 (0.47) | CLPPMMP13 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6949651-B2 | Fused bicyclic metalloproteinase inhibitors | WARNER-LAMBERT COMPANY (US) | 2005-09-27 | — | — | US | disclosed |
| US-20040034054-A1 | Fused bicyclic metalloproteinase inhibitors | LINCOLN FOODSERVICE PRODUCTS INC. | 2004-02-19 | — | — | US | disclosed |
| WO-2004014375-A2 | FUSED BICYCLIC METALLOPROTEINASE INHIBITORS | WARNER-LAMBERT COMPANY LLC (US) | 2004-02-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040034054-A1 | Fused bicyclic metalloproteinase inhibitors | MMP9, MMP1, MMP2 | PLA2G7 189/4885PDE3B 1507/4885PDE3A 1554/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.